Evidence map›Paper›PMID 40067636›Full record

ReviewPharmacological reports : PR2025

Carvacrol in asthma management: a comprehensive review of its therapeutic potential and mechanisms of action.

Deepa Neopane, Poonam Kushwaha

Abstract readReview
PubMed Publisher
In one paragraph

Review in Pharmacological reports : PR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Role of Carvacrol in Oral Health: An Overview.Current pharmaceutical design · 2026
    Review
  2. Analysis of Pharmacological Properties ofLife (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Deepa NeopaneFaculty of Pharmacy, Integral University, Lucknow, Uttar Pradesh, 226026, India.
Poonam KushwahaFaculty of Pharmacy, Integral University, Lucknow, Uttar Pradesh, 226026, India. poonam.kushwaha083@gmail.com.ORCID https://orcid.org/0000-0002-4478-8325

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Asthma, a chronic inflammatory disorder of the airways, remains a significant global health concern. Current treatments focus on symptom management and inflammation control, but the search for more effective and safer therapies continues. Carvacrol, a naturally occurring monoterpenoid phenol found in essential oils of various plants, has emerged as a promising bioactive compound with potent anti-inflammatory, antioxidant, and bronchodilatory properties. This review explores the potential of carvacrol as a novel therapeutic agent for asthma management. We discuss its mechanisms of action, including modulation of inflammatory pathways, inhibition of oxidative stress, and relaxation of bronchial muscles. Additionally, preclinical and clinical studies evaluating the efficacy and safety of carvacrol in asthma treatment are analyzed. The integration of carvacrol into existing treatment regimens could offer a multifaceted approach to asthma management, enhancing therapeutic outcomes and improving patients' quality of life.

Indexed as

Anti-Asthmatic AgentsAnti-Inflammatory AgentsAsthmaCymenesMonoterpenesAnimalsAntioxidantsHumansOxidative StressQuality of LifeAnti-Asthmatic AgentsAnti-Inflammatory AgentsAntioxidantscarvacrolCymenesMonoterpenesAnti-inflammatoryAntioxidantAsthmaBronchodilationCarvacrolClinical applicationsPreclinical studies

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.